- Home
- HKD vs BCYC Comparison
HKD vs BCYC Comparison
Compare HKD & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKD
- BCYC
- Stock Information
- Founded
- HKD 2003
- BCYC 2009
- Country
- HKD France
- BCYC United Kingdom
- Employees
- HKD N/A
- BCYC N/A
- Industry
- HKD Finance: Consumer Services
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- HKD Finance
- BCYC Health Care
- Exchange
- HKD Nasdaq
- BCYC Nasdaq
- Market Cap
- HKD 656.8M
- BCYC 565.5M
- IPO Year
- HKD 2022
- BCYC 2019
- Fundamental
- Price
- HKD $1.68
- BCYC $6.80
- Analyst Decision
- HKD
- BCYC Buy
- Analyst Count
- HKD 0
- BCYC 11
- Target Price
- HKD N/A
- BCYC $20.73
- AVG Volume (30 Days)
- HKD 17.4M
- BCYC 345.3K
- Earning Date
- HKD 01-01-0001
- BCYC 10-30-2025
- Dividend Yield
- HKD N/A
- BCYC N/A
- EPS Growth
- HKD N/A
- BCYC N/A
- EPS
- HKD N/A
- BCYC N/A
- Revenue
- HKD $87,436,000.00
- BCYC $28,339,000.00
- Revenue This Year
- HKD N/A
- BCYC N/A
- Revenue Next Year
- HKD N/A
- BCYC N/A
- P/E Ratio
- HKD $14.27
- BCYC N/A
- Revenue Growth
- HKD N/A
- BCYC N/A
- 52 Week Low
- HKD $1.55
- BCYC $6.10
- 52 Week High
- HKD $5.47
- BCYC $25.39
- Technical
- Relative Strength Index (RSI)
- HKD 45.42
- BCYC 41.33
- Support Level
- HKD $1.76
- BCYC $6.19
- Resistance Level
- HKD $1.99
- BCYC $9.08
- Average True Range (ATR)
- HKD 0.42
- BCYC 0.50
- MACD
- HKD -0.03
- BCYC -0.18
- Stochastic Oscillator
- HKD 0.91
- BCYC 23.49
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.